Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review

Table 3 Overall survival and disease-free survival of patients after neoadjuvant chemotherapy and surgery versus upfront surgery

Ref.	Overall survival		P value	Disease-free survival		P value
	NAT	US		NAT	US
Ahn et al[8], 2014	NS	NS		NS	NS
Biondi et al[9], 2018	> 60 mo	45 mo	0.519	NS	NS
Bracale et al[10], 2021	72%	71%	0.41	71%	75%	0.34
Eom et al[11], 2018	73.3%	51.1%	0.005	62.8%	49.9%	0.145
Feng et al[12], 2015	NS	NS		NS	NS
Wang et al[13], 2021	63.3%	50%	0.215	60%	33.3%	0.019
Xue et al[14], 2018	70%	74%	> 0.05	NS	NS
Kang et al[15], 2021	74.2%	73.4%	> 0.05	66.3%	60.2%	0.023
Kano et al[16], 2019	NS	NS		80%	58.7%	0.037
Lin et al[17], 20221	Eastern: 60.1%. Western: 57.3%	Eastern: 49.3%. Western: 39.5%	Eastern: 0.02. Western: 0.11	NS	NS
Marino et al[18], 2021	50 mo	35 mo	> 0.05	48 mo		> 0.05
Molina et al[19], 2013		39.01%			34.05%
Pardo et al[20], 2020	41.6%	38.6%	0.089	NS	NS
Wang et al[21], 2019	58.7%	30.9%	0.008	NS	NS
Wang et al[22], 2021	52 mo	26.4 mo	< 0.001	NS2	NS2
Wu et al[23], 2019	NS	NS		NS	NS
Xu et al[24], 2021	72.29%	36.22%	< 0.001	58.53%	30.87%	< 0.001
Zhao et al[25], 2017	17.9 mo	17.4 mo	> 0.05	16.1 mo	15.8 mo	> 0.05

¹All patients received neoadjuvant chemotherapy; adjuvant chemotherapy (first column) and non-adjuvant chemotherapy groups (second column) were compared in two independent (an eastern and a western) cohorts.

²Not stated for neoadjuvant chemotherapy vs upfront surgery. But nCRT (chemoradio-) significantly better than nCT (chemo-) (P = 0.014).

NAT: Neoadjuvant chemotherapy; US: Upfront surgery; NS: Not stated.